Mission
The mission of HESI’s Genomics Committee is to advance the scientific basis for the development and application of genomic methodologies to mechanism-based risk assessment; to address scientific issues relating to the use of these new technologies as a means for understanding toxic response and mechanisms; and to provide a scientific forum for a consensus-based approach to interpreting and applying these data.
The HESI Genomics Committee executes its mission via multiple working groups with distinct projects and activities. Active programs include a study using microarray data to assess doxorobucin toxicity in rodents (the study will compare array data with other metrics such as histopathology and serum chemistry) and planning for a workshop featuring case studies of the use of toxicogenomic data for safety and risk assessment. The Committee is completing manuscripts on control animal microarray data, use of genomics and PCR to distinguish direct and indirect acting genotoxins, and the results of a survey on the current state of practice in the field of toxicogenomics.
Proposal submittal deadline: July 30, 2010
|
|
|
Committee Participation
2010 Government and Academic Participation
European Medicines Agency (EMEA)
Georgetown University
Harvard University
Michigan State University
National Institute of Health Sciences (Japan)
National Institute for Public Health and the
Environment (RIVM, The Netherlands)
US Department of Agriculture
US Environmental Protection Agency
US Food and Drug Administration
US National Center for Toxicological Research
US National Institute of Environmental Health Sciences
2010 Committee Membership
Abbott Laboratories
Actelion
Allergan, Inc.
Amgen, Inc.
Astellas Phama Inc.
AstraZeneca AB
Bayer HealthCare Pharmaceuticals
Boehringer Ingelheim GmbH
Daiichi Sankyo Co., Ltd.
Eli Lilly and Company
F. Hoffmann-La Roche Inc.
GlaxoSmithKline
Institut de Recherches Internationales SERVIER
Johnson & Johnson Pharmaceuticals
Novartis Pharmaceuticals Corporation
Pfizer Inc.
sanofi-aventis
Sumitomo Chemical Co., Ltd.
Syngenta Ltd.
Takeda Pharmaceutical Company Limited
Unilever PLC
|
|
Contact:
Chair:
Jiri Aubrecht, PhD
Pfizer Global Research & Development
Vice Chair:
Richard S. Paules, PhD
National Institute of Enviromental Health Sciences
HESI Staff:
Dr. Raegan O'Lone, rolone@hesiglobal.org
Ms. Regina Graham
(202) 659-3306
|
